OBJECTIVE-Carnosinase 1 (CN1) is a secreted dipeptidase that hydrolyzes L-carnosine. Recently, we have identified an allelic variant of human CN1 (hCN1) that results in increased enzyme activity and is associated with susceptibility for diabetic nephropathy in human diabetic patients. We therefore hypothesized that L-carnosine in the serum represents a critical protective factor in diabetic patients. RESEARCH DESIGN AND METHODS-L-carnosine serum levels were manipulated in db/db mice, a model of type 2 diabetes. In a transgenic approach, hCN1 cDNA was expressed under the control of a liver-specific promoter in db/db mice, mimicking the expression pattern of hCN1 in humans. RESULTS-Fasting plasma glucose as well as A1C levels rose significantly earlier and remained higher in transgenic animals throughout life. Body weights were reduced as a result of significant glucosuria. In an opposite approach, nontransgenic db/db mice were supplemented with L-carnosine. In these latter mice, diabetes manifested significantly later and milder. In agreement with the above data, serum fasting insulin levels were low in the transgenic mice and elevated by L-carnosine feeding. Insulin resistance and insulin secretion were not significantly affected by L-carnosine serum levels. Instead, a significant correlation of L-carnosine levels with ␤-cell mass was observed. CONCLUSIONS-hCN1-dependent susceptibility to diabetic nephropathy may at least in part be mediated by altered glucose metabolism in type 2 diabetic patients. Diabetes 56:2425-2432, 2007 P atients with type 2 diabetes often suffer serious complications of chronic hyperglycemia, including nephropathy, neuropathy, retinopathy, and accelerated development of cardiovascular disease. The prevalence of type 2 diabetes worldwide is 6% and projected to rise over the next decade, owing to the increasing age of the population and the surge of obesity (1). There is evidence of a genetic component in the risk for type 2 diabetes, including prevalence differences between racial groups and higher concordance rates among monozygotic than dizygotic twins (2). There is also evidence for a genetic component to the risk of diabetic nephropathy (3,4).
and projected to rise over the next decade, owing to the increasing age of the population and the surge of obesity (1) . There is evidence of a genetic component in the risk for type 2 diabetes, including prevalence differences between racial groups and higher concordance rates among monozygotic than dizygotic twins (2) . There is also evidence for a genetic component to the risk of diabetic nephropathy (3, 4) .
Our group is interested in identifying variants of genes that modify the risk for diabetes complications, such as diabetic nephropathy. Recently, an association of diabetic nephropathy and an allelic variant within the leader peptide of carnosine dipeptidase 1 (carnosinase 1 [CN1]), which affected the efficiency of enzyme secretion, was identified and subsequently confirmed (5, 6) . CN1 is a dipeptidase that hydrolyzes L-carnosine (␤-alanyl-L-histidine) and to a lesser extent homocarnosine (7) . The variant with the smallest number of leucine repeats was more common in the absence of diabetic nephropathy and was associated with lower CN1 serum levels. Leader peptide variants containing more than five leucine repeats were associated with an increased risk for diabetic nephropathy. From these genetic data in human patients, it was hypothesized that L-carnosine serum levels are associated with the risk for late complications of diabetic disease and that L-carnosine acts as a protective factor (6) .
Thus far, the function of the atypical dipeptide L-carnosine remains unknown. L-carnosine is present intracellularly in most tissues. The highest levels of L-carnosine are found in muscle and also in the central nervous system, where it is released into the serum and cerebrospinal fluid, respectively. L-carnosine is also ingested into the serum from food. In humans, L-carnosine is degraded predominantly by CN1, which is secreted from the liver into the serum (7) . In other mammals, including rodents, CN1 is expressed exclusively within the kidney and lacks a signal peptide. In these animals, L-carnosine is eliminated from the serum by filtration into the urine and reabsorption into tubular cells, which express CN1 within the cytosol (7) . CN1 expression levels vary among different mouse strains, and C57BL/6J mice, used in this study, express particularly low levels of endogenous CN1 in their kidneys (8) .
This study was undertaken to verify the genetic association of CN1 with diabetic disease and to test whether CN1 determines the risk for diabetic nephropathy through L-carnosine. L-carnosine levels were manipulated in the serum of a type 2 diabetes mouse model. This was achieved by two experimental approaches. First, endogenous L-carnosine serum levels were artificially lowered by overexpression of secreted human CN1 (hCN1) under the control of a liver-specific promoter mimicking the endogenous expression pattern of CN1 in humans. In a second experimental approach, diabetic mice were given L-carnosine in their drinking water.
Measurement of carnosine concentration in mouse EDTA plasma was performed according to the method of Schonherr (14) with modifications. Moreover, 80 l EDTA plasma was mixed with 20 l 10% 5-sulfosalicylic acid, 10 l supernatant was mixed with 20 l 0.4 mol/l borate buffer (pH 9.5), and 10 l supernatant was mixed with 10 mol/l standard carnosine solution. Blank values, carnosine concentration standards, and carnosine composition standards (anserine, histidine) were prepared for each measurement in parallel with the samples.
For derivatization, 30 l of each sample was mixed with 30 l of freshly prepared CFC solution (2.5 mmol/l in acetone). After 90 s, 18 l 1 mmol/l EDTA in 0.1 mol/l NaOH and 0.5 mol/l hydroxylamine hydrochloride in distilled water and 2-methylthioethanol was added. After an additional 3 min, 42 l quench solution, 20% (vol/vol) acetic acid in acetonitrile, was added. Then 40 l of diluted sample was injected for separation into the highperformance liquid chromatography system LaChrom Elite HPLC system (Jupiter column, C18, 300 Å, 5 m particle size; Phenomenex, Aschaffenburg, Germany). The elution was performed with fluorescence detection at 287 nm extinction and 340 nm emission. The profile of the binary gradient was as follows: 0 -45 min, 82% A and 18% B; 46 -50 min, 18 -100% B; 50 -55 min, 100% B; 56 -60 min, 100 -18% B; and 60 -80 min, 82% A and 18% B. The retention times strongly depended on the mobile phase composition. Histological analysis. At the end of the observation period, animals were killed at 24 weeks of age and perfused with 3% paraformaldehyde as described (15) . Semi-thin kidney sections, 1 m thick, were evaluated by two renal pathologists in a blinded fashion for mesangial expansion. At least 50 glomeruli were evaluated from each experimental animal; mesangial expansion was classified into three groups: 0, no mesangial expansion; 1, mild; and 2, significant mesangial expansion. Cell culture. The insulin-producing INS-1e cells were cultured in RPMI-1640 supplemented with HEPES, 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin/streptomycin, 1 mmol/l sodium pyruvate, and 100 mol/l 2-mercaptoethanol (16) . The cells were exposed to various stimuli for 2 h in Krebs-Ringer bicarbonate HEPES buffer (n ϭ 3); 5 mmol/l L-glutamine served as negative control, and L-glutamine and 20 mmol/l L-leucine or 30 mmol/l KCl served as positive control (Sigma-Aldrich, Munich, Germany). Insulin levels were analyzed as a ratio, where basal insulin secretion in the presence of only L-glutamine was normalized to 1. To assess the proliferative index, INS-1e cells were pulsed with BrdU for 2 h, fixed, and stained using an anti-BrdU antiserum (MAB3424; Chemicon International, Hampshire, U.K.).
RESULTS
Generation of hCN1 transgenic db/db mice. To lower L-carnosine level within the serum of diabetic mice, the cDNA of hCN1 was placed under the control of the human transthyretin promoter enhancer (TTP promoter) (Fig. 1) . The TTP promoter was chosen because it drives expression in hepatocytes as well as the choroid plexus, recapitulating the expression pattern of endogenous hCN1 in humans (9) . Low-level expression of transgenic hCN1 was also seen in ␣-cells of the pancreatic islets ( Fig. 2D-F) . Rodents do not endogenously express a secreted form of CN1 (7, 8) . The cDNA of hCN1 contained the endogenous signal peptide so that transgenic hCN1 was secreted into the serum and liquor in vivo as in humans.
The transgene was introduced by pronuclear injection into fertilized eggs derived from heterozygous db/db mice. This mouse line carries a point mutation within the leptin receptor that leads to its functional inactivation resulting in hyperphagia after weaning, obesity, hyperinsulinemia, and elevated plasma glucose levels (type 2 diabetes model) from week 8. The BKS.Cg-m ϩ/ϩ Lepr db/J mouse has been shown to be susceptible to diabetic nephropathy (17) . Mice were genotyped for the transgene hCN1 as well as the leptin receptor mutation (Lepr) by PCR from genomic DNA preparations of tail biopsies. Of 70 mice, 15 mice were transgenic for hCN1 (21%). All of the results described below were reproduced in at least four different founder lines. A stable line with robust CN1 expression was established from heterozygous db/wt hCN1 transgenic founder mice by crossbreeding with nontransgenic db/wt littermates (line 13). Analysis of hCN1 transgenic db/db mice. Messenger RNA was isolated from liver and kidney of hCN1 transgenic db/db mice and from nontransgenic littermates. Nonsaturated RT-PCR analysis using primers specific for transgenic hCN1 demonstrated expression of transgenic mRNA within liver but not kidney ( Fig. 2A , transgenic hCN1). TTP-hCN1 plasmid was used as positive control. Expression of endogenous cytosolic CN1 was detected in kidney, as described previously ( Fig. 2A , endogenous mCN1). Gel electrophoresis of total RNA as well as nonsaturating RT-PCR specific for endogenous ␤-actin was used to control for equal loading. Negative controls omitting reverse transcription (Fig. 2 , RTϪ) or omitting mRNA (Fig. 2 , water only) were always negative.
To verify that the transgenic hCN1 is efficiently secreted into the serum, 10 l of serum derived from hCN1 transgenic (db/db CN1ϩ) or nontransgenic (db/db water) controls were subjected to SDS-PAGE and subsequently immunoblotted with various anti-sera directed against CN1. No CN1 protein was detected in nontransgenic controls, as described previously (7). Significant amounts of CN1 protein were detected in hCN1 transgenic animals (arrow).
To verify the functional effects of hCN1 overexpression, L-carnosine levels were measured in EDTA plasma obtained at the beginning of the light cycle of transgenic and control db/db mice ( Fig. 2C ) at 12 weeks of age. In control mice, endogenous L-carnosine levels averaged ϳ1.2 Ϯ 0.5 mol/l. In hCN1 transgenic mice, L-carnosine levels were significantly lower (P Ͻ 0.01), most values below the detection level of 0.02 mol/l (Fig. 2C , db/db CN1ϩ). Analysis of db/db mice supplemented with L-carnosine. A second experimental group of nontransgenic db/db mice was supplemented with L-carnosine in the drinking water. L-carnosine plasma levels were signifi-
FIG. 2. Manipulation of L-carnosine serum levels in db/db mice. A:
Messenger RNA expression of hCN1 and endogenous CN1 in liver and kidney of wild-type (db/db water) and transgenic db/db (db/db CN1؉) mice was evaluated by RT-PCR. Expression of endogenous CN1, which is not secreted into the serum, was detected within the kidney, while transgenic hCN1 was expressed in liver. Total RNA and RT-PCR for ␤-actin verifies equal loading; hCN1 plasmid was used as positive control. Controls omitting reverse transcription (RT-) or using water only were negative. B: Serum (10 l) of transgenic and wild-type db/db mice was submitted to SDS-PAGE and anti-hCN1 immunoblot analysis. Equal protein load was verified by Ponceau's staining. Transgenic hCN1 was detected at ϳ50 kDa and only in the serum of transgenic db/db CN1؉ mice (arrow). C: L-carnosine concentrations were measured in the serum of hCN1-transgenic and wild-type db/db mice and in wild-type db/db mice that received L-carnosine in their drinking water (db/db carnosine) (n ‫؍‬ 5 for each group). L-carnosine levels were lowered from baseline levels of 1.2 mol/l to below minimal detection levels in transgenic db/db mice and elevated to 6 mol/l in L-carnosine-supplemented mice. D-F: Immunohistological staining for CN1 on pancreatic sections revealed low-level ectopic transgene expression within the pancreatic islets of founder line 13 
that was selected for this study (D). A single founder line (4) showed significant ectopic transgene expression within pancreatic islets (E). No staining was observed in nontransgenic littermates (F).
cantly elevated to 6 Ϯ 1.1 mol/l in this group (n ϭ 6 for each group) (Fig. 2C , db/db carnosine). FPG levels correlate inversely with L-carnosine levels. Normal db/db mice (db/db water) developed persistent hyperglycemia between weeks 8 and 10 (Fig. 3A , db/db water), as described (18) . hCN1 transgenic db/db mice (db/db CN1ϩ) developed hyperglycemia earlier (weeks 6 -7) and reached significantly higher FPG levels than the db/db water group. Conversely, FPG levels were significantly lower in L-carnosine-supplemented mice (Fig. 3A , db/db L-carnosine), and the onset of diabetes was delayed until weeks [17] [18] [19] [20] . Similarly, A1C levels were elevated in hCN1 transgenic mice (db/db CN1ϩ) and significantly improved in L-carnosine-supplemented mice (db/db carnosine) compared with wild-type diabetic db/db mice (Fig.  3B , db/db water).
Obesity is important for the pathogenesis of altered glucose metabolism in the db/db mouse model. As expected, total body weights increased in parallel in all experimental diabetic groups until week 8. From week 15 onwards, hCN1 transgenic mice started to lose weight until they reached the weight of nondiabetic db/wt control mice by week 22 (Fig. 3C , db/db CN1ϩ). This progressive wasting ultimately led to the death of the mice between 24 and 28 weeks of age, as verified by autopsy; four mice died of dehydration and one of an intra-abdominal abscess. The observation period of this study was therefore limited to 23 weeks ( Supplementary Fig. 1 [available in an online appendix at http://dx.doi.org/10.2337/db07-0177]). No ketones were detected within spot-urine samples, and no significant differences in food or water intake were observed until week 20 (not shown). Significant glucosuria of ϳ1.7 g/day was observed in the db/db CN1ϩ group (Fig.  3D) .
L-carnosine-supplemented mice continued to gain weight beyond week 15 until the end of the observation period (Fig. 3C, db/ metabolism was aggravated in hCN1 transgenic db/db mice as a consequence of increased body mass. Correlation of insulin secretion with L-carnosine serum levels. Compared with diabetic controls (db/db water), insulin levels were decreased in hCN1 transgenic mice despite higher FPG levels (Fig. 4A) . The opposite pattern was observed in L-carnosine-supplemented mice (db/db L-carnosine), where serum insulin levels were significantly increased with lower FPG levels compared with those of diabetic controls (db/db water). These results suggested that glucose metabolism was primarily affected by altered insulin secretion in hCN1 transgenic and Lcarnosine-supplemented mice.
To validate these findings, insulin sensitivity tests were performed (Fig. 4B, age 12 weeks) . FPG levels fell proportionally in all experimental groups (20% reduction after 30 min, 30% total reduction after 1 h), indicating that peripheral insulin sensitivity is similar within the experimental groups. Glucose tolerance tests were also performed (Fig.  4C) . A similar rise in FPG levels was observed in Lcarnosine-supplemented mice (db/db L-carnosine) and diabetic control mice (db/db water). FPG levels in hCN1 transgenic mice (db/db CN1ϩ) exceeded the range of the glucose test (600 mg/dl). In summary, a direct correlation of L-carnosine serum levels with insulin levels was detected in our experimental mice, whereas peripheral insulin sensitivity was unaltered. Islet hyperplasia in L-carnosine-supplemented mice. To investigate the mechanism by which L-carnosine serum levels affect insulin secretion, pancreatic glands were removed from the experimental animals at 24 weeks of age, paraffin embedded, and subjected to histological analysis ( Fig. 5A-E) . Islet size was determined by morphometry (Fig. 5E) . Overall, pancreatic islets were enlarged in diabetic mice compared with those in controls (db/wt). A striking difference in pancreatic islet size was observed in L-carnosine-supplemented animals ( Fig. 5D and E). Hyperplastic islets of L-carnosine-supplemented mice were predominantly composed of insulin-producing ␤-cells, as demonstrated by immunohistological anti-insulin staining (Fig. 5F) .
Next, it was tested whether L-carnosine exerts a direct effect on insulin secretion or proliferation of ␤-cells in vitro. For this purpose, INS-1e cells were exposed to varying concentrations of L-carnosine. INS-1e cells are derived from ␤-cells and secrete insulin in a highly regulated glucose-dependent manner (16) . In the absence of L-carnosine, insulin secretion increased in the presence of increasing concentrations of L-glucose, as expected (Fig.  5G , open columns). Exposure to various concentrations of L-carnosine did not significantly affect glucose-dependent insulin secretion in INS-1e cells (gray, striped, and filled columns). Statistically significant increments of insulin secretion were detected for higher concentrations of Lcarnosine in the absence of L-glucose (Fig. 5G, 0G , 1 mM and 20 mM L-carnosine). However, no significant influence of lower near-physiological levels of L-carnosine on insulin secretion was detected in the absence of L-glucose.
In a second set of experiments, INS-1e cells were cultured at low densities in the presence of varying concentrations of L-carnosine for 3 days. The percentage of BrdU-positive cells in three independent experiments is shown in Fig. 5H . A dose-dependent increase in BrdUpositive cells was observed with increasing L-carnosine concentrations.
These data suggested that insulin secretion was preserved in L-carnosine-supplemented mice because of an increased or preserved mass of ␤-cells within the pancreas. No significant stimulatory effect of L-carnosine on insulin secretion was observed in vitro, at least near physiological levels. Diabetic nephropathy. Because CN1 has been identified as a risk factor for diabetic nephropathy in diabetic humans, it was investigated whether L-carnosine serum levels affect the kidney in our mouse model. Serum creatinine levels were lowest in hCN1 transgenic animals (db/db CN1ϩ) and correlated with the extent of polyuria or glomerular filtration rate as a result of poor glycemic control (Fig. 6A) . Serum urea levels showed significantly elevated levels in hCN1 transgenic mice as a consequence of impaired renal function or dehydration (Fig. 6B) . Albumin-to-creatinine ratios were significantly increased in all diabetic experimental groups (db/db CN1ϩ, db/db water, and db/db carnosine) compared with nondiabetic controls (db/wt), indicating the presence of diabetic nephropathy in all diabetic groups (Fig. 6E) . However, no significant differences between L-carnosine-supplemented and CN1 transgenic animals were observed at 15 or 20 weeks of age.
Renal hypertrophy is an early sign of diabetic nephropathy. At 23 weeks of age, absolute kidney weights were significantly increased in all diabetic animals compared with those of nondiabetic controls (Fig. 6C, db/wt) . How- ever, no significant differences were observed among the diabetic experimental groups. The ratio of kidney weight over total body weight (Fig. 6D ) suggested significant renal hypertrophy only in transgenic diabetic mice (db/db CN1ϩ). However, the ratio failed to demonstrate renal hypertrophy in normal diabetic db/db mice (db/db water). It was concluded that kidney-to-body weight ratios are not a suitable parameter in this model because body weights were significantly affected by modulation of L-carnosine serum levels, as shown in Fig. 3C .
Finally, mesangial expansion as a sign for diabetic nephropathy was assessed. A representative example for "no mesangial expansion" is shown in Fig. 6G (control) and for "significant mesangial expansion" in Fig. 6H (mes. expansion). In agreement with the results described above, mesangial expansion was present in all three diabetic groups (Fig. 6F ) compared with nondiabetic db/wt mice, but no significant differences between any of the diabetic groups could be detected in this mouse model.
DISCUSSION
In this study, an association of CN1 activity with diabetic disease, previously identified in human diabetic patients (6) , was confirmed in a type 2 diabetes mouse model. This association was mediated by the substrate of CN1, Lcarnosine. Interestingly, in the type 2 diabetes db/db mouse model described here, L-carnosine primarily affected glucose metabolism. L-carnosine serum levels did not significantly affect diabetic nephropathy, as suggested by an initial genetic study in human patients (6) .
The results of this study contribute significantly to our understanding of the genetic association in humans. In humans, the "high-risk" group of patients carried more efficient signal peptides within the hCN1 gene (i.e., with more than five leucines), resulting in higher CN1 activity and lower L-carnosine levels with the serum (6) . Consistent with the human data, hCN1 transgenic diabetic mice with lower L-carnosine serum levels were affected by more severe diabetic disease in this study. In a different experimental approach in this study, L-carnosine levels were artificially raised in db/db mice and associated with improved glucose metabolism. This indicates that the human genetic association between CN1 activity and diabetes complications is a consequence of a primary effect on glucose metabolism and that hCN1 is a modifier gene for diabetic disease. A direct effect of the quality of control on glucose metabolism and late diabetes complications has been established in human patients (19, 20) . In the initial study by Janssen et al. (6) , metabolic control of diabetic disease was evaluated during the later stages of diabetes (i.e., after Ͼ15 years). It is possible that the higher prevalence of diabetes complications in the high-risk group of human diabetic patients reflected poor metabolic control of diabetes in this group (6) .
Further support that hCN1 activity modifies glucose metabolism in human patients comes from a study that performed a genome scan for loci associated with increased FPG levels in families afflicted in part by obesity (21) . Significant linkages were found with a trait located at chromosome 18q22 (logarithm of odds 4.4 -6.6), the region where CNDP1 (hCN1) is located with ϳ150 other genes. No correlation of the identified locus and BMI was observed by Li et al. (21) , supporting that decreased body weights in hCN1 transgenic mice were primarily a consequence of calorie loss in the urine in this study.
In humans, the trait on locus 18q22 only affected the FPG levels, not the prevalence of overt diabetic disease, as shown by Li et al. (21) . Likewise, L-carnosine levels only affected the extent and severity diabetic disease in our type 2 diabetic mouse model-overt diabetes with FPG levels Ͼ200 mg/dl manifested significantly earlier in hCN1 transgenic mice or later in L-carnosine-supplemented mice, but eventually all mice became diabetic. Metabolic control in L-carnosine-supplemented mice eventually be- Lower creatinine and elevated urea levels were observed in transgenic mice (db/db CN1؉). Serum creatinine levels were highest in nondiabetic db/wt control mice. C: Absolute kidney weight (in grams) and kidney-to-body weight ratio (D) were determined. Renal hypertrophy was observed in all diabetic experimental groups compared with nondiabetic controls (db/wt). No significant differences in kidney weight were observed among the diabetic groups db/db CN1؉, db/db Carnosine, or db/db water. D: Kidney-to-body weight ratios showed significant differences among the diabetic experimental groups; however, this effect only reflected the differences in body weight among the groups. E: Albumin and creatinine concentrations were measured at 15 and 20 weeks of age in 24-h urine collections. Albumin-to-creatinine ratios (alb./creat. ratio) were significantly increased in all diabetic experimental groups compared with nondiabetic controls (db/wt). No significant differences were observed among CN1 transgenic (db/db CN1؉), L-carnosine-supplemented (db/db Carnosine), and control diabetic (db/db water) mice. F: Semi-thin sections of the kidneys were evaluated in a blinded fashion by two independent renal pathologists for mesangial expansion (0, normal; 1, mild expansion; 2, strong expansion; 50 glomeruli for each animal). Representative images are shown in G (normal) and H (strong expansion, arrows). Significant mesangial expansion was observed in all diabetic experimental groups compared with nondiabetic controls (db/wt). No significant differences were observed among db/db CN1؉, db/db Carnosine, and db/db water mice.
came worse, similar to diabetic controls, indicating that L-carnosine is not sufficient to prevent overt diabetes.
Our results are also in agreement with the initial finding by Janssen et al. (6) that the risk for poor control of diabetes (reflected by a higher risk for diabetic nephropathy) is inherited in an autosomal-dominant fashion. A single CNDP1 allele with an efficient leader peptide for secretion (i.e., with more than five leucins) was sufficient to decrease serum L-carnosine levels, which were associated with poor diabetes control.
In this study, L-carnosine levels primarily affected serum insulin secretion, as indicated by the inverse correlation of body weights to FPG levels, insulin levels, and functional tests of glucose metabolism. Our data suggest that insulin secretion is preserved because of an increased ␤-cell mass as a consequence of increased L-carnosine serum levels. In addition to that, a discrete effect of L-carnosine on glucoseindependent insulin secretion was observed in vitro, which can be expected from an amino acid or a small dipeptide such as L-carnosine.
In summary, CN1 is a potential target for pharmacological interventions aimed at manipulating glucose metabolism. Since only approximately one-third of the entire human population is homozygous for the "low-risk" CNDP1 allele (5, 6, 22) , this approach has the potential for a broad applicability to diabetic patients.
